Kineta rises on resuming enrollment in early-stage cancer study

Kineta

19/08/2024 15:44

** Shares of drug developer Kineta  KA.O  rise 13.5% to 64
cents 
    ** Co says it has resumed enrollment, effective immediately,
for its ongoing early-stage trial testing its experimental
cancer treatment- KVA12123
    ** Co previously said enrollment was suspended "due to
certain investors indicating that they would not fulfill their
funding obligation due in April 2024" 
    ** Co says 30 patients have been enrolled in the trial to
date, including a monotherapy arm with just KVA12123 and a
combination arm testing KVA12123 together with Merck's  MRK.N 
Keytruda  
   ** Anticipates the trial to be fully enrolled by the end of
2024- KA 
   ** Co says initial results of KVA12123 showed a favorable
clinical safety and tolerability profile
    ** Including session moves, stock down 82.1% YTD 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))